课题基金 / 基金详情

Targeting 14-3-3zeta to promote human pancreatic beta-cell proliferation

Targeting 14-3-3zeta to promote human pancreatic beta-cell proliferation
靶向 14-3-3zeta 促进人胰腺 β 细胞增殖
批准号:
414919
负责人:
Lim Gareth E
金额:
$7.29万
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2019
资助国家:
加拿大
项目状态:
已结题
起止时间:
2019-09-01 至 2020-09-01

项目摘要

项目成果

Lim Gareth E的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Type 1 diabetes (T1D) is a devastating disease caused by the death of insulin-producing pancreatic beta-cells by our own immune system. There is no cure for T1D, and current treatment involves daily injections of insulin to keep blood glucose levels with
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Canada Research Chair - Tier 2
  • 批准号:
    481072
  • 项目类别:
  • 资助金额:
    $36.43万
  • 财政年份:
    2022
  • 负责人:
    Lim Gareth E
  • 依托单位:
Targeting 14-3-3zeta to increase beta-cell proliferation and function to treat Type 1 Diabetes
Canada Research Chair Tier 2
  • 批准号:
    392600
  • 项目类别:
  • 资助金额:
    $36.43万
  • 财政年份:
    2018
  • 负责人:
    Lim Gareth E
  • 依托单位:
Targeting molecular scaffolds for the treatment of obesity and metabolic disease
海外基金